Carisma Therapeutics, Inc. (CARM): Valuation
TTM figures as of September 30, 2025
Carisma Therapeutics, Inc. trades at 0.0 times trailing earnings and a -66,958.30% free-cash-flow yield. On P/E that is higher than 7% of its own month-end history back to 2014. The Healthcare median P/E is 22.9.
Earnings yield 24,023.14%. Net cash $2.8M.
151 month-end valuation observations are on file, starting February 2014.
Sector comparison uses 2682 Healthcare names.
Frequently asked questions
Is CARM cheap versus its own history?
Carisma Therapeutics, Inc. trades at 0.0 times trailing earnings and a -66,958.30% free-cash-flow yield. On P/E that is higher than 7% of its own month-end history back to 2014. The Healthcare median P/E is 22.9.
What is CARM's free-cash-flow yield?
Carisma Therapeutics, Inc. currently yields -66,958.30% of market cap as trailing free cash flow.
Where do these valuation figures come from?
Yields and quality metrics are computed from the same SEC TTM figures as the financials page, against the live market cap. Historical bands reconstruct month-end market cap from split-adjusted closes and the share count in the units it was filed, then divide by those dollar totals. Nothing here is a third-party estimate.